6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $292M | $554000 | 0.0% | 8.5% | — | $220M | $111M |
| 2024 | $203M | -$55M | 0.0% | -16.6% | — | $232M | $72M |
| 2023 | $164M | -$62M | 0.0% | -26.8% | — | $191M | $67M |
| 2022 | $110M | -$95M | 0.0% | -74.3% | — | $187M | $122M |
| 2021 | $50M | -$123M | 0.0% | -232.2% | -$97M | $88M | $67M |
| 2020 | $20M | -$91M | 0.0% | -414.5% | -$81M | $87M | $38M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $83M | $2M | 0.0% | 9.5% | — | $221M | $112M |
| Dec '25 | $86M | $11M | 0.0% | 19.5% | — | $220M | $111M |
| Sep '25 | $74M | $621000 | 0.0% | 9.0% | — | $219M | $92M |
| Jun '25 | $72M | -$2M | 0.0% | 6.3% | — | $219M | $59M |
| Mar '25 | $60M | -$9M | 0.0% | -5.1% | — | $230M | $58M |
| Dec '24 | $60M | -$5M | 0.0% | 2.8% | — | $232M | $72M |
| Sep '24 | $54M | -$16M | 0.0% | -23.8% | — | $216M | $59M |
| Jun '24 | $48M | -$15M | 0.0% | -17.0% | — | $230M | $58M |
| Mar '24 | $41M | -$19M | 0.0% | -35.1% | — | $230M | $63M |
| Dec '23 | $44M | -$13M | 0.0% | -22.2% | — | $191M | $67M |
| Sep '23 | $48M | -$12M | 0.0% | -10.2% | — | $190M | $46M |
| Jun '23 | $38M | -$20M | 0.0% | -42.0% | — | $188M | $46M |
| Mar '23 | $33M | -$17M | 0.0% | -40.0% | — | $188M | $51M |
| Dec '22 | $33M | -$13M | 0.0% | -45.8% | — | $187M | $122M |
| Sep '22 | $30M | -$22M | 0.0% | -63.2% | — | $139M | $84M |
| Jun '22 | $25M | -$26M | 0.0% | -74.7% | — | $138M | $95M |
| Mar '22 | $22M | -$34M | 0.0% | -131.7% | — | $138M | $104M |
| Dec '21 | $21M | -$51M | 0.0% | -225.3% | -$29M | $88M | $67M |
| Sep '21 | $11M | -$26M | 70.9% | -220.2% | — | $88M | $59M |
| Jun '21 | $9M | -$28M | 0.0% | -289.5% | — | — | — |
How the market has priced XERS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Xeris Biopharma Holdings, Inc.'s revenue has grown 70.7% per year. These are computed facts, not advice.
As of FY2025, Xeris Biopharma Holdings, Inc. reported $220M of total debt against $111M of cash; operating income covered interest expense 0.9×.
In FY2025, gross margin was —, operating margin 8.5%, and net margin 0.2%.
As of Jun '26, Xeris Biopharma Holdings, Inc. traded at a price-to-earnings ratio of about 2309.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.